Difference between revisions of "Zoledronic acid (Zometa)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 1: Line 1:
 
==General information==
 
==General information==
Class: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf Zoledronic acid (Zometa) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/zoledronicacid.pdf Zoledronic acid (Zometa) package insert (locally hosted backup)]</ref>
+
Class: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf Zoledronic acid (Zometa) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/zoledronicacid.pdf Zoledronic acid (Zometa) package insert (locally hosted backup)]</ref><ref>[http://www.zometa.com Zometa manufacturer's site]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>.  
  
 
==Patient drug information==
 
==Patient drug information==

Revision as of 03:31, 26 February 2012

General information

Class: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].

Patient drug information

References